Heart failure & cardiomyopathies
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials
Authors' conclusion
Among patients with HF, irrespective of their LVEF and clinical status, the addition of SGLT2i to SOC demonstrated a significant improvement in quality of life as early as at 3-month follow-up.
Study context
- Population
- Patients with heart failure (HF) irrespective of left ventricular ejection fraction (LVEF)
- Participants
- 21,737 patients14 randomized clinical trials (RCTs)
- Comparison
- SGLT2 inhibitor added to standard of care vs standard of care alone
- Outcome
- Difference in mean change of KCCQ-OSS from baseline
- Follow-up
- 3 and 6 months
Pooled result
As reported in the abstract
KCCQ-OSS mean change
SGLT2i vs SOCDifference in mean change, points (95% CI)
3 months
1.94(1.41–2.46)
6 months
2.18(1.13–3.24)
Further pooled results
Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) change over time in both groups
- Significant improvement over time with both standard of care (SOC) and SGLT2i
- P < 0.001
KCCQ-OSS by HF status (subgroup)
- Greater improvement with recent worsening HF than chronic stable HF
Original publication
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →